Silence Therapeutics (NASDAQ:SLN) Price Target Cut to $25.00 by Analysts at BMO Capital Markets

Silence Therapeutics (NASDAQ:SLN) had its target price decreased by BMO Capital Markets from $67.00 to $25.00 in a research note published on Tuesday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Several other equities analysts have also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. The Goldman Sachs Group reduced their price objective on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Finally, Chardan Capital reissued a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $4.74 on Tuesday. The stock has a 50-day moving average of $5.44 and a two-hundred day moving average of $11.48. The company has a market cap of $141.87 million, a P/E ratio of -3.02 and a beta of 1.08. Silence Therapeutics has a 1-year low of $4.06 and a 1-year high of $27.72.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Eventide Asset Management LLC purchased a new position in shares of Silence Therapeutics in the third quarter valued at $11,635,000. Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after purchasing an additional 208,029 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Silence Therapeutics by 32.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Silence Therapeutics during the 3rd quarter valued at about $207,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.